Inrebic and Yosprala

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of fedratinib, which is a substrate of the isoenzyme. However, clinical data evaluating the interaction are not available. MANAGEMENT: Caution is recommended with the concomitant use of fedratinib and CYP450 2C19 inhibitors. Patients should be monitored for adverse effects including anemia, thrombocytopenia, diarrhea, nausea, vomiting, and liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations. References "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.

MONITOR: Coadministration with CYP450 2C19 inhibitors may increase the plasma concentrations of fedratinib, which is a substrate of the isoenzyme. However, clinical data evaluating the interaction are not available.

MANAGEMENT: Caution is recommended with the concomitant use of fedratinib and CYP450 2C19 inhibitors. Patients should be monitored for adverse effects including anemia, thrombocytopenia, diarrhea, nausea, vomiting, and liver (ALT, AST) and pancreatic (amylase, lipase) enzyme elevations.

Inrebic

Generic Name: fedratinib

Brand name: Inrebic

Synonyms: n.a.

What is Inrebic?

Yosprala

Generic Name: aspirin / omeprazole

Brand name: Yosprala

Synonyms: n.a.

What is Yosprala?